Concepedia

Himachandana Atluri

HA

Statistics

Publications

4

Citations

79

H-Index

4

Active since

2022

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Himachandana Atluri is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, pharmacology, and cancer pharmacology.

ORCID

Publications per year

2022–2024

4

Publications

4

A randomized feasibility study evaluating temozolomide circadian medicine in patients with glioma

Anna R. Damato, Ruth Katumba, Jingqin Luo et al. · Neuro-Oncology Practice · 2022 · 36 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib: 2023 Update

Himachandana Atluri, Jillian Mullin, Koichi Takahashi et al. · Blood · 2023 · 18 citations

Medicine, Pharmacology, Pharmacotherapy +6

Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Nitin Jain, Alessandra Ferrajoli, Mahesh Swaminathan et al. · Blood · 2024 · 15 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia

Himachandana Atluri, Abhishek Maiti, Koji Sasaki et al. · Blood · 2022 · 10 citations

Medicine, Pharmacology, Pharmacotherapy +14

1–4 of 4